{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:37:37Z","timestamp":1791923857867,"version":"4.3.4"},"reference-count":30,"publisher":"BMJ","issue":"15","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Swedish government","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2023,2,14]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Beta-blockers (BB) are an established treatment following myocardial infarction (MI). However, there is uncertainty as to whether BB beyond the first year of MI have a role in patients without heart failure or left ventricular systolic dysfunction (LVSD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A nationwide cohort study was conducted including 43\u2009618 patients with MI between 2005 and 2016 in the Swedish register for coronary heart disease. Follow-up started 1\u2009year after hospitalisation (index date). Patients with heart failure or LVSD up until the index date were excluded. Patients were allocated into two groups according to BB treatment. Primary outcome was a composite of all-cause mortality, MI, unscheduled revascularisation and hospitalisation for heart failure. Outcomes were analysed using Cox and Fine\u2013Grey regression models after inverse propensity score weighting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 34\u2009253 (78.5%) patients received BB and 9365 (21.5%) did not at the index date 1\u2009year following MI. The median age was 64 years and 25.5% were female. In the intention-to-treat analysis, the unadjusted rate of primary outcome was lower among patients who received versus not received BB (3.8 vs 4.9 events\/100 person-years) (HR 0.76; 95%\u2009CI 0.73 to 1.04). Following inverse propensity score weighting and multivariable adjustment, the risk of the primary outcome was not different according to BB treatment (HR 0.99; 95%\u2009CI 0.93 to 1.04). Similar findings were observed when censoring for BB discontinuation or treatment switch during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Evidence from this nationwide cohort study suggests that BB treatment beyond 1 year of MI for patients without heart failure or LVSD was not associated with improved cardiovascular outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/heartjnl-2022-322115","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T20:35:23Z","timestamp":1683059723000},"page":"1159-1165","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":42,"title":["Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes"],"prefix":"10.1136","volume":"109","clinical-trial-number":[{"clinical-trial-number":"nct03646357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03278509","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03778554","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03596385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03498066","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03646357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03278509","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03778554","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03596385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03498066","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Divan","family":"Ishak","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleman","family":"Aktaa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"},{"name":"Division of Epidemiology and Biostatistics, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lindhagen","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Alfredsson","sequence":"additional","affiliation":[{"name":"Department of Health, Medicine and Caring Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"},{"name":"Department of Cardiology, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8337-8425","authenticated-orcid":false,"given":"Tatendashe Bernadette","family":"Dondo","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8960-2125","authenticated-orcid":false,"given":"Troels","family":"Yndigegn","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris P","family":"Gale","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"},{"name":"Division of Epidemiology and Biostatistics, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-9547","authenticated-orcid":false,"given":"Gorav","family":"Batra","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"2025100705044658000_109.15.1159.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"2025100705044658000_109.15.1159.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa624"},{"key":"2025100705044658000_109.15.1159.3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025100705044658000_109.15.1159.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2025100705044658000_109.15.1159.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.12559"},{"key":"2025100705044658000_109.15.1159.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.114.001073"},{"key":"2025100705044658000_109.15.1159.7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/FJC.0000000000001221","article-title":"Long-term beta-blocker therapy after myocardial infarction without heart failure in the reperfusion era-systemic review and meta-analysis","volume":"79","author":"Kim","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025100705044658000_109.15.1159.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.05.032"},{"key":"2025100705044658000_109.15.1159.9","article-title":"Beta-blockers for suspected or diagnosed acute myocardial infarction","volume":"12","author":"Safi","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025100705044658000_109.15.1159.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198104023041401"},{"key":"2025100705044658000_109.15.1159.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1981.03320180063037"},{"key":"2025100705044658000_109.15.1159.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199303113281001"},{"key":"2025100705044658000_109.15.1159.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706053362301"},{"key":"2025100705044658000_109.15.1159.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"2025100705044658000_109.15.1159.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199347","article-title":"Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"13","author":"Watanabe","year":"2018","journal-title":"PLoS One"},{"key":"2025100705044658000_109.15.1159.16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/eurheartj\/ehaa1058","article-title":"Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study","volume":"42","author":"Holt","year":"2021","journal-title":"Eur Heart J"},{"key":"2025100705044658000_109.15.1159.17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ehjcvp\/pvaa029","article-title":"Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction","volume":"7","author":"Joo","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025100705044658000_109.15.1159.18","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/eurheartj\/ehaa376","article-title":"Long-term \u03b2-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study","volume":"41","author":"Kim","year":"2020","journal-title":"Eur Heart J"},{"key":"2025100705044658000_109.15.1159.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4801","article-title":"\u03b2 blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study","volume":"354","author":"Puymirat","year":"2016","journal-title":"BMJ"},{"key":"2025100705044658000_109.15.1159.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.578"},{"key":"2025100705044658000_109.15.1159.21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.004356","article-title":"Clinical events after discontinuation of \u03b2-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases","volume":"11","author":"Neumann","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025100705044658000_109.15.1159.22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2204"},{"key":"2025100705044658000_109.15.1159.23","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000109691.16944.DA"},{"key":"2025100705044658000_109.15.1159.24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000172","article-title":"Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia","volume":"2","author":"Hung","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2025100705044658000_109.15.1159.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.09.006"},{"key":"2025100705044658000_109.15.1159.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00873-5"},{"key":"2025100705044658000_109.15.1159.27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ahj.2006.02.030","article-title":"National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance","volume":"152","author":"Kramer","year":"2006","journal-title":"Am Heart J"},{"key":"2025100705044658000_109.15.1159.28","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2025100705044658000_109.15.1159.29","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0316-1"},{"key":"2025100705044658000_109.15.1159.30","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.2724","article-title":"Association of beta-blockers beyond 1 year after myocardial infarction for patients without heart failure or left ventricular systolic dysfunction and cardiovascular outcomes: nationwide cohort study","volume":"43","author":"Ishak","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2022-322115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:10:35Z","timestamp":1759839035000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2022-322115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":30,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,7,12]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/heartjnl-2022-322115"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2022-322115","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}